Alabamians' access to and views about Alzheimer's treatments
Access, Preferences, and Costs for Alzheimer’s Disease Treatment in Alabama (AccessAL-AD)
This project looks at how older adults in Alabama get, pay for, and feel about new Alzheimer’s treatments like lecanemab.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11343006 on NIH RePORTER |
What this research studies
This project will talk with people living with Alzheimer’s, caregivers, clinicians, and health system staff across Alabama to learn where care is hard to reach and what costs and barriers look like. Researchers will use interviews and other qualitative methods to explore five access domains (availability, accessibility, affordability, accommodation, and acceptability). They will combine what they learn with an economic model to estimate long-term costs and benefits of new Alzheimer’s drugs in Alabama. The work pays special attention to practical issues such as specialist visits, brain imaging, infusion delivery, travel, and out-of-pocket costs.
Who could benefit from this research
Good fit: Older adults in Alabama with Alzheimer’s disease, their caregivers, and clinicians who care for them are the main people who would be invited to take part.
Not a fit: People who do not live in Alabama or who do not have ties to local Alzheimer’s care are unlikely to benefit directly from this project.
Why it matters
Potential benefit: Findings could help make it easier and more affordable for Alabamians with Alzheimer’s to get new treatments and guide local policies and programs.
How similar studies have performed: Health services and cost studies have informed access to other expensive treatments, but applying mixed qualitative work and economic modeling to new Alzheimer’s antibodies in Alabama is relatively new.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Pisu, Maria — University of Alabama at Birmingham
- Study coordinator: Pisu, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.